Bridge Health
Full Brand & Product Review
Overall Rating: 3.7 / 10
REGISTRATION
UK, 2015
PRODUCT OPTIONS
ivermectin 12mg
(30/60/120 caps)
INDEPENDENT CoA
BIOSYNTH Group
PRODUCER
not disclosed
SUBSIDIARY BRANDS
Overview
Bridge Health is a registered UK company that publishes a Certificate of Analysis from a verifiable laboratory. Against the backdrop of the brands covered in this series, that already puts it in a different category. But the COA itself, when read carefully, tells a more complicated story than the product listings suggest. And several structural questions about the company remain unanswered.
Criteria Ratings
1. Information Transparency | 4 / 10
Bridge Health Limited is registered⇥ at Companies House under number 09513124, incorporated March 26, 2015.
The registered address is Wilkin Chapman LLP, The Maltings, 11-15 Brayford Wharf East, Lincoln, LN5 7AY. Wilkin Chapman is a law firm.
Using a solicitor's address as a registered office is legally acceptable in the UK, but it means the address does not reflect any physical operational base.
The registered SIC code is 86101, which corresponds to hospital activities.
The company sells research compounds. No explanation for this mismatch appears anywhere on the website or in any filing.
The Feefo profile⇥ for Bridge Health lists a third address: 85 Great Portland Street, London, W1W 7LT.
This is separate from the Companies House solicitor's address in Lincoln and from the unnamed GMP manufacturing facility. 85 Great Portland Street is a known virtual office location in London.
The company therefore has at least three addresses across its public-facing records, none of which corresponds to a named production site.
No director name is published on the website.
The About Us page describes the company as "a UK based pharmaceutical company with global reach" that sources, manufactures, and distributes pharmaceutical compounds.
No named individual, no founding team, and no operational address beyond the solicitor's office is publicly visible.
The About page states that manufacturing partners hold GMP certification and that products are "produced in the UK with direct traceability."
The name of the manufacturing facility is not disclosed anywhere on the website or in any product documentation.
2. Label Accuracy | 3 / 10
The published COA shows purity of 94 area-% by HPLC.
The COA specification for this material lists the minimum as 90 area-%. The product meets the minimum specification.
It does not exceed BP/USP standards.
Both the British Pharmacopoeia and the United States Pharmacopeia require not less than 95% purity for ivermectin.
The published result of 94% falls below both reference standards, directly contradicting the Amazon listing claim.
The Amazon listing for IverMec⇥ 12 states the product undergoes "a rigorous purification process, guaranteeing a purity level that exceeds BP/USP and EU standards."
3. Product Definition | 4 / 10
The product is presented as ivermectin 12mg capsules with GMP manufacture in a UK facility. The active ingredient and dose are stated. No excipients or inactive ingredients are listed on the product page or in any accessible documentation. The COA covers the active ingredient only. What fills the remaining capsule volume and what the capsule shell is made of is not disclosed anywhere.
The bottle does not carry a tamper-proof seal.
One verified purchaser noted this specifically, gave 3 stars on that basis alone, and stated they would switch to a different brand for their next purchase. 12 people found that review helpful.
One buyer received multiple empty capsules in the same bottle.
4. Manufacturer Traceability | 3 / 10
Bridge Health publishes its COA on a dedicated Reports page⇥. The document is a real laboratory report from BIOSYNTH Group, a legitimate chemical supplier. It is not AI-generated, not illegible, and not a placeholder.
Only one lot is listed on the ivermectin reports page. The COA is dated December 2, 2024. No subsequent lot reports have been published. No indication is given of how frequently testing occurs or whether each production batch is tested independently.
The manufacturing facility is not named. GMP certification is claimed for unnamed partners. No GMP certificate, no facility registration number, and no MHRA licensing reference is provided.
The COA carries a QR code that links directly to the Biosynth product listing⇥ for FI24744.
That listing describes the product as intended "for pharmaceutical testing" as a "high-quality reference standard."
Reference standards are analytical tools used to verify the purity of other materials in laboratory settings.
They are not intended as bulk active pharmaceutical ingredients for encapsulation and commercial sale.
The COA Bridge Health publishes is a reference standard certification, not a bulk manufacturing input certification.
The report is issued under BIOSYNTH's own reference numbers (PA No.: 142193, Internal Reference No.: 4500138668). It covers a raw material lot (BIOSYNTH Lot No. 247441551) tested at the point of supply.
The lot number on the COA does not match the lot identifier used by Bridge Health (BH/I12/02325). No document links the BIOSYNTH lot to the finished capsules sold under the Bridge Health lot code.
5. Availability & Distribution | 5 / 10
Products are available through bridge-health.co and Amazon UK. Multiple capsule counts are offered and the storefront functions. Bridge Health also sells fenbendazole and DMSO.
Ivermectin in tablet or capsule form is not licensed for human use in the United Kingdom⇥. The only MHRA-authorised ivermectin product in the UK is Soolantra, a topical cream for rosacea.
Selling ivermectin capsules on Amazon UK sits in a regulatory grey area. Bridge Health addresses this with a disclaimer stating all products are intended for research use only.
6. Public Feedback Patterns | 3 / 10
Bridge Health maintains a Feefo profile⇥ listing 85 Great Portland Street, London as its contact address. At the time of this investigation, the profile showed five reviews in total. For a company incorporated in 2015 and presenting itself as a pharmaceutical company with global reach, five reviews across a decade of trading is a thin public record.
Feefo is a paid subscription platform. Bridge Health pays for the service, which means the company is a client of the review platform hosting its feedback. Multiple independent accounts on Trustpilot describe Feefo as a platform that filters out negative reviews, publishing only positive ones. This context is relevant when evaluating the five reviews visible on the Bridge Health profile.
The Amazon UK reviews across Bridge Health products paint a consistent picture of packaging and fulfilment failures.
One verified purchaser reviewed the fenbendazole 30caps product and wrote:
Poor quality packaging, clearly not manufactured in the UK as claimed, capsules contain other additives, not just Fenbendazole as claimed."
43 people found that review helpful. This is the highest helpfulness count of any Bridge Health review found in this investigation and directly challenges two of the brand's core claims across its entire product range.
A second Amazon buyer gave 2 stars and noted:
"The QR code should link to the specification sheet but doesn't. Worrying!"
This is consistent with this investigation's finding that the QR code on the COA links to a Biosynth reference standard product page rather than to any product-specific specification document.
Two further Amazon buyers left 1-star reviews.
One ordered 30 fenbendazole capsules and received 29. Another reported nine days without any sign of their order and no explanation or apology.
For IverMec 12 specifically, one verified purchaser gave 3 stars because the bottle arrived without a tamper-proof seal, stating they would switch brands next time.
12 people found that review helpful.
A second buyer received multiple empty capsules in the same bottle.
Empty capsules, a missing tamper seal, a short-count bottle, a QR code linking nowhere useful, and a direct dispute of the UK manufacturing claim collectively describe a brand whose quality control record does not support its GMP positioning.
Summary Scorecard
Main Conclusion
Main Conclusion
Bridge Health is a registered UK company that publishes a real COA from a verifiable laboratory. That is where the straightforward part ends.
The QR code on the COA links to a Biosynth product page describing FI24744 as a pharmaceutical testing reference standard, not a bulk manufacturing ingredient. At least one Amazon buyer noticed the same problem independently, writing that the QR code should link to a specification sheet but does not. The lot number on the COA does not match the lot identifier on the product and no document connects the two. The published purity result of 94% falls below the 95% threshold required by both BP and USP pharmacopoeial standards, directly contradicting the Amazon listing claim that purity exceeds those standards.
Amazon reviews across Bridge Health products raise questions that go beyond documentation. One verified purchaser of the fenbendazole product, with 43 people finding their review helpful, wrote that the capsules were clearly not manufactured in the UK as claimed and contained additives not disclosed on the label. Buyers have also received IverMec 12 bottles with no tamper-proof seal, bottles with multiple empty capsules, and fenbendazole bottles with one capsule short of the stated count.
The company shows three separate addresses across its public records: a law firm in Lincoln, a virtual office in London on Feefo, and an unnamed GMP facility. It is registered under a hospital activities SIC code despite selling research compounds. No director is named publicly. Five Feefo reviews across ten years of trading does not reflect the scale implied by a global pharmaceutical company claim, and Feefo's status as a paid platform adds further context to those five visible reviews.